FGF21 and Cognitive impairment: As FGF21 has been proposed as a potential therapeutic agent for AD and Parkinson’s disease (PD) [12,70], investigating whether GLN-mediated FGF21 production exerts beneficial effects in animal models of AD and PD could inform potential therapeutic strategies for neurodegenerative diseases or cognitive impairment in the future.